Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
1.16
Industry P/E
--
Debt to Equity
0
ROE
-1.4 %
ROCE
-1.15 %
Div. Yield
0 %
Book Value
370.35
EPS
-2.15
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Impact BioMedical, Inc (IBO)
| -70.14 | -91.27 | -72.25 | -- | -- | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.90 | 9,808.03 | 20.22 | 23.13 | |
| 291.44 | 8,956.09 | 22.08 | 58.42 | |
| 26.70 | 9,559.25 | -- | -28.77 | |
| 104.01 | 10,030.35 | 30.81 | 14.16 |
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare,... and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Address: 1400 Broadfield Blvd., Houston, TX, United States, 77084 Read more
CFO. Secretary & Treasurer
Mr. Todd D. Macko
Chairman & CEO
Mr. Frank D. Heuszel Esq., J.D.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Impact BioMedical, Inc (IBO) stood at $ 20 Mln as on 31-Dec-24
The share price of Impact BioMedical, Inc (IBO) is $0.43 (NYSE) as of 23-Apr-2025 12:32 EDT. Impact BioMedical, Inc (IBO) has given a return of --% in the last 1 years.
Impact BioMedical, Inc (IBO) has a market capitalisation of $ 5 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Impact BioMedical, Inc (IBO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Impact BioMedical, Inc (IBO) and enter the required number of quantities and click on buy to purchase the shares of Impact BioMedical, Inc (IBO).
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Address: 1400 Broadfield Blvd., Houston, TX, United States, 77084
The CEO & director of Mr. Todd D. Macko. is Impact BioMedical, Inc (IBO), and CFO & Sr. VP is Mr. Frank D. Heuszel Esq., J.D..
There is no promoter pledging in Impact BioMedical, Inc (IBO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Impact BioMedical, Inc. (IBO) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.15
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Impact BioMedical, Inc (IBO) was $0 Mln.
$0.01
(
